Back to Search Start Over

Incidence, recurrence and management of electrical storm in Brugada syndrome.

Authors :
El-Battrawy I
Roterberg G
Kowitz J
Aweimer A
Lang S
Mügge A
Zhou X
Akin I
Source :
Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2022 Oct 25; Vol. 9, pp. 981715. Date of Electronic Publication: 2022 Oct 25 (Print Publication: 2022).
Publication Year :
2022

Abstract

Background: Brugada syndrome (BrS) is associated with ventricular tachyarrhythmias. However, the presence of electrical strom (ES) and its management still debated.<br />Objectives: We present the outcome and management of 44 BrS patients suffering from ES.<br />Methods: A systematic literature review and pooled analysis Through database review including PubMed, Web of Science, Cochrane Libary and Cinahl studies were analyzed. Evidence from 7 reports of 808 BrS patients was identified.<br />Results: The mean age of patients suffering from ES was 34 ± 9.5 months (94.7% males, 65.8% spontaneous BrS type I). Using electrophysiological study ventricular tachycardia/ventricular fibrillation were inducible in 12/23 (52.2%). Recurrence of ES was documented in 6.1%. Death from ES was 8.2% after a follow-up of 83.5 ± 53.4. In up to 27 ES resolved without treatment. External shock was required in 35.6%, internal ICD shock in 13.3%, Overdrive pacing, left cardiac sympathetic block and atropin in 2.2%. Short-term antiarrhythmic management was as the following: Isopreterenol or Isopreterenol in combination with quinidine 35.5%, orciprenaline in 2.2%, quinidine 2.2%, disopyramide 2.2% or denopamide 2.2%. However, lidocaine, magensium sulfate, mexiletine and propanolol failed to control ES.<br />Conclusion: Although ES is rare in BrS, this entity challenges physicians. Despite its high mortality rate, spontaneous termination is possible. Short-term management using Isoproterenol and/or quinidine might be safe. Prospective studies on management of ES are warranted.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 El-Battrawy, Roterberg, Kowitz, Aweimer, Lang, Mügge, Zhou and Akin.)

Details

Language :
English
ISSN :
2297-055X
Volume :
9
Database :
MEDLINE
Journal :
Frontiers in cardiovascular medicine
Publication Type :
Academic Journal
Accession number :
36386327
Full Text :
https://doi.org/10.3389/fcvm.2022.981715